Update shared on18 Oct 2025
Fair value Decreased 0.46%The fair value estimate for DSM-Firmenich has been slightly reduced from €108.95 to €108.45. This change reflects updated analyst projections citing modest adjustments to revenue growth and profit margin expectations.
Analyst Commentary
Recent analyst updates on DSM-Firmenich highlight a mix of optimistic and cautious views following the latest price target adjustments. The revised projections indicate ongoing debate regarding the company’s near-term growth prospects and its ability to navigate current market dynamics.
Bullish Takeaways
- Bullish analysts continue to maintain their Buy ratings, even as price targets moderate. This signals ongoing confidence in DSM-Firmenich’s fundamental strengths and long-term prospects.
- Some view the current valuation as attractive relative to anticipated earnings improvements. This suggests potential for recovery as headwinds subside.
- Expectations remain for gradual normalization in profit margins. There are hopeful signs that recent efficiency measures will begin to bolster financial performance over time.
- Analysts see the company’s diversified business structure as supportive of resilience and believe this could underpin revenue stability in a challenging environment.
Bearish Takeaways
- Bearish analysts have further reduced their price targets, pointing to persistent concerns about weaker revenue growth and pressure on margins.
- There is ongoing caution regarding DSM-Firmenich’s ability to execute amid sector challenges. Some analysts question the pace and scale of recovery in core divisions.
- Lowered ratings reflect doubts about near-term upside, as headwinds in end markets and slower momentum could weigh on financial results.
- Some analysts warn that forecasts may need further downward revision if macroeconomic softness persists. This could potentially lead to additional derating of the company’s valuation.
What's in the News
- DSM-Firmenich AG announced that Lacteol®, the top pediatrician-recommended postbiotic product in France, is now available in the United States as Lacteol® diarrhEase™ Kids. The product offers a drug-free digestive solution for children aged six months and up (Key Developments).
- The company's buyback program concluded with the repurchase of 4,580,734 shares, representing 1.73% of share capital, for €432 million between February 13, 2025 and July 30, 2025 (Key Developments).
Valuation Changes
- Fair Value Estimate has been reduced slightly from €108.95 to €108.45, reflecting a modestly more cautious outlook.
- Discount Rate has decreased marginally from 6.03% to 6.01%, suggesting a minimal shift in perceived risk.
- Revenue Growth expectations have been lowered from 2.21% to 2.14%, indicating a slightly more conservative forecast for sales expansion.
- Net Profit Margin projection has edged down from 8.45% to 8.42%, pointing to a minor dip in anticipated profitability.
- Future P/E Ratio is nearly unchanged, moving from 28.89x to 28.88x, which highlights stable valuation multiples despite recent adjustments.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.